Logo

AltheaDx NeuroIDgenetix Test Expansion

Dec 17, 2015

AltheaDx has expanded NeuroIDgenetix, the neuropsychiatric component of its IDgenetix pharmacogenetics (PGx) testing portfolio. The panel now includes PGx testing for medication used to treat both bipolar disorder and seizure disorder. The addition of these two new offerings means the panel now includes a total of six tests for neuropsychiatric disorders (depression, anxiety, bipolar disorder, ADHD, psychosis, and seizure disorder) and four tests for pain (arthritis, migraine, musculoskeletal pain, and neuropathic pain). The expanded panel evaluates a total of 128 FDA-approved neuropsychiatric and pain medications, including mood stabilizers for bipolar disorder and a variety of anticonvulsant medications used to treat seizure disorders. The panel also analyzes 15 clinically validated genes, including those involved in drug metabolism and those that influence individual response to a variety of different medications. 

Breaking News
The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.